FDA clears Roche and Lilly Alzheimer’s blood tests, while Regenxbio gene therapy trial halted again
read at raps ↗RegulatoryNeutral
The U.S. Food and Drug Administration announced it has granted clearance for blood-based diagnostic tests for Alzheimer’s disease developed by Roche and Eli Lilly.
The clearances allow the companies to market the tests, which could expand early detection options for patients and potentially influence clinical practice.
In a separate action, the FDA again halted a gene-therapy trial conducted by Regenxbio, marking a repeat stoppage of the study.
source
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Recon: FDA clears Roche, Lilly Alzheimer’s blood tests; Regenxbio gene therapy trial halted by FDA again”
read at raps ↗
comments(0)
5-min edit window · permanent after that